Listen on the go
CORRECT!
Next question
touchOPHTHALMOLOGY touchOPHTHALMOLOGY
Glaucoma

Sarah Van Tassel, Kiaweh Eye 2021: New Drugs and Drug Delivery Options for Glaucoma Management

Share this Video
Copy Link
Published Online: Jul 9th 2021

It was a pleasure to speak with Sarah Van Tassel (Weill Cornell Medicine, NY, USA) on her thoughts about the new therapeutic options for glaucoma management and the promising new combinations on the horizon.

  1. How has the pharmaceutical landscape for glaucoma developed in the last year? (00:12)
  2. Where do rho-kinase inhibitors sit in the treatment paradigm for glaucoma? (02:17)
  3. What promising new drugs and combinations are in the pipeline? (03:46)

Speaker Disclosure: Sarah Van Tassel has received speaker’s fees from the following: Aerie, Allergan, Zeiss, New World Medical, Equinox Ophthalmic.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of Kiaweh Eye 2021.

Related Videos In Glaucoma
Glaucoma
Developed by Touch
Ticiana De Francesco, AGS 2023: Corneal endothelial cell safety profile of three different MiGS stents
Watch Time: 4 mins

Endothelial cell safety is an important factor to consider when selecting early surgical treatment for glaucoma patients. It was a pleasure to speak with Dr Ticiana De Francesco (Hospital de Olhos Leiria de Andrade (HOLA) Fortaleza, Brazil) around her study on comparing the effect of cataract surgery and iStent inject, Hydrus micro-stent, or CyPass micro-stent […]

Glaucoma
Developed by Touch
Ticiana De Francesco, AGS 2023: Minimally invasive glaucoma surgery (MiGS) devices in glaucoma management
Watch Time: 3 mins

Minimally invasive glaucoma surgery (MiGS) devices have revolutionised in glaucoma management, achieving reliable IOP reduction with a favorable safety profile and quick postoperative recovery. It was a pleasure to speak with Dr Ticiana De Francesco (Hospital de Olhos Leiria de Andrade (HOLA) Fortaleza, Brazil) to find out her thoughts in the current status of minimally invasive glaucoma […]

Glaucoma
Developed by Touch
Luis Abegão Pinto: World Glaucoma Week 2023
Watch Time: 6:08 mins

World Glaucoma Week kicks off on 12 March, 2023, with the aim of raising awareness of the impact of this devastating disease. The key to preventing needless vision impairment is prompt diagnosis and treatment. However, many are unaware they have the disease or do not have access to much-needed care. This is particularly true in […]

Trending In Glaucoma:

Ticiana De Francesco, AGS 2023: Corneal endothelial cell safety profile of three different MiGS stents
Glaucoma
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72